Introduction {#sec1}
============

The mammary serine protease inhibitor (MASPIN), encoded by the human serpin family B member 5 (*SERPINB5*) gene, was first reported in 1994 as a tumor suppressor \[[@B1]\]. MASPIN is highly expressed in normal mammary epithelial cells but is often down-regulated or not expressed in the progression of breast malignant tumors \[[@B1],[@B2]\]. Advanced research found that MASPIN inhibits cell invasion, promotes apoptosis, and inhibits angiogenesis, so it is considered to have class II tumor-suppressive properties \[[@B3]\]. MASPIN localizes in not only primarily cytoplasm (in the mammary epithelial cells), but also nucleus (in the myoepithelial cells), secretory vesicles, and cell surface \[[@B4]\]. MASPIN subcellular localization appears linked to its biological functions \[[@B5]\], and its nuclear localization indicates a more favorable prognosis in human malignancies, such as breast cancer \[[@B6]\], pancreatic cancer \[[@B4]\], and ovarian carcinoma \[[@B7]\]. This phenomenon also appears in non-small cell lung cancer (NSCLC) \[[@B8]\], which is one of the most familiar malignant tumors \[[@B9],[@B10]\] and can be mainly divided into lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD), and lung large cell carcinoma, pathologically \[[@B11]\]. One study shows emaciated cytoplasmic MASPIN expression could consider as an independent positive predictor in primary NSCLC \[[@B12]\], whereas another study shows that dominant nuclear expression was related to positive prognosis in resectable NSCLC \[[@B13]\]. This paradoxical localization and expression of MASPIN might have cell-specific characteristics \[[@B14]\] and play different roles in NSCLC. Moreover, MASPIN may have an ability to limit malignancy cell phenotypic plasticity and affect the cancer cell response to drugs \[[@B15]\], so it might be a valuable marker and potential therapeutic agent \[[@B5]\]. Thus, we conducted present study to clarify the roles of MASPIN expression and subcellular localization in NSCLC.

Materials and methods {#sec2}
=====================

Studies search and selection {#sec2-1}
----------------------------

We performed a systematic search on Medline, Embase, and Web of Science (WOS) for relevant published studies from inception to 31 January 2019, with language restricted to English. The following keywords were used in different combinations: 'Carcinoma', 'Non-Small-Cell Lung', 'MASPIN', 'SERPIN-B5', 'Prognosis'. Search strategies in Medline were available in Supplementary Table S1.

Inclusion criteria for studies: (1) participants were pathologically diagnosed with NSCLC; (2) the expression and subcellular localization were detected by immunohistochemistry; (3) patients were divided into high and low expression groups according to MASPIN expression and the relationship between MASPIN and NSCLC prognosis (such as overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and disease-specific survival (DSS)) and clinicopathological characteristics were described; (iv) relevant data were sufficient to obtain hazard ratio (HR) and corresponding 95% confidence interval (CI); (v) cohort studies. Exclusion criteria included reviews, case reports, comments, expert opinions, meta-analysis, and conference summaries. When studies or data duplication were found, only the latest or most complete studies were included.

Data extraction and management {#sec2-2}
------------------------------

Citations were screened at the title and abstract level by two independent reviewers, and the full text was retrieved for those potentially eligible. For studies that did not provide HRs and 95% CIs directly, we estimated them through indirect methods \[[@B16]\]. If only Kaplan--Meier curves were available, HRs were extracted from graphics by Engauge Digitizer \[[@B17]\]. One reviewer extracted data of interest into a predesigned excel spreadsheet. Then, another two reviewers checked received data and contradictory cases were resolved by the final author.

Quality assessment {#sec2-3}
------------------

Two reviewers critically and independently assessed included studies using the Newcastle--Ottawa Scale (NOS) \[[@B18],[@B19]\]. The assessments include selection, comparability, and outcome. The studies were divided into three grades: low, medium, and high, with NOS scores ranging from 0 to 3, 4 to 6, and 7 to 9, respectively. All data were finally shown in the predesigned excel spreadsheet and discrepancies, contradictories were resolved by the third author.

Data synthesis and analysis {#sec2-4}
---------------------------

The STATA, statistical software for data science, was adopted to synthesize and analyze data. Similar to the method described previously \[[@B20]\], heterogeneity was assessed by *I^2^* tests. If the data were substantially homogeneous, a synthesis was directly conducted with the fixed-effect model. Otherwise, a synthesis was directly conducted with the random-effect model, successively subgroup analysis was performed. Sensitivity analysis was additionally conducted to investigate the robustness of our results. At last, the funnel plot and Egger's tests were applied to assess for publication bias. Later, the different subcellular location was also analyzed.

Bioinformatics analysis {#sec2-5}
-----------------------

The *SERPINB5* mRNA and protein expression between NSCLC and normal tissue were studied using UALCAN \[[@B21]\] and Human Pathology Atlas \[[@B22]\], respectively. The association between *SERPINB5* and OS or PFS and the clinicopathological significances of *SERPINB5* in NSCLC were all conducted in the Kaplan--Meier plotter \[[@B23]\]. The patients were grouped by median *SERPINB5* expression and HR with 95% CI were calculated. In addition, MethHC \[[@B24]\] was utilized to compare the *SERPINB5* promoter region methylation between NSCLC and normal tissue as well as the relationship between mRNA expression and methylation in NSCLC patients. One-way ANOVA was used to analyze differential expression. Moreover, the genes co-expressed with *SERPINB* in TCGA-LUAD were identified using the cBioPortal \[[@B25]\]. Only those genes with Spearman's correlation coefficients of more than 0.4 were identified as *SERPINB*-related genes. Finally, *SERPINB*-related genes were loaded into DAVID \[[@B26],[@B27]\] for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and the illustration of the biological significance was performed using the *clusterProfiler* package in R \[[@B28]\].

Results {#sec3}
=======

Characteristics of eligible studies {#sec3-1}
-----------------------------------

The primary search of all sources yielded 222 articles eligible for identification. A total of 186 title/abstracts were screened for eligibility after removing 36 duplicates. Of these, 19 full-text articles were assessed for eligibility. Finally, a total of 12 studies \[[@B12],[@B29]\] were included in the present study ([Figure 1](#F1){ref-type="fig"}).

![Flow diagram of the selection process in this meta-analysis](bsr-40-bsr20200743-g1){#F1}

Twelve studies comprising 2220 patients contained information regarding OS, PFS, DFS, and DSS. All included studies were published in 2005 and later, and more than half of the studies were conducted in Japan \[[@B12],[@B31],[@B39]\], only three studies involved LUSC or LUAD \[[@B31],[@B33],[@B34]\]. Only one study did not report gender composition \[[@B37]\]. Two studies did not report the median age \[[@B31],[@B37]\], and the median age of the included individuals was approximately 65 years old or so. Only two studies had no staging information for NSCLC \[[@B36],[@B37]\]. As for subcellular localization, three studies \[[@B12],[@B30],[@B34]\] only involved cytoplasm, while others included both cytoplasm and nucleus. Some HRs were extracted directly from corresponding studies \[[@B29]\], and some were extracted from corresponding curve \[[@B12],[@B32],[@B35]\], and some were not reported \[[@B29],[@B32],[@B38]\]. The included studies also had different definitions of the cut-off value. NOS scores of all eligible studies were greater than 7. The main characteristics of the included studies are shown in [Table 1](#T1){ref-type="table"}.

###### Main characteristics of eligible studies

  Author, year       Country       Type            No. (M/F)      Median age   Stage              Location   Cut-off         Positive (%)            Median follow-up        Outcome                                 HR estimation             NOS
  ------------------ ------------- --------------- -------------- ------------ ------------------ ---------- --------------- ----------------------- ----------------------- --------------------------------------- ------------------------- -----
  Hirai, 2005        Japan         A94/S38         132 (90/42)    65.5         I-II78/III54       C          ≥40%            73 (55.3%)              NR (1--42 m)            Negative (NSCLC+C)                      OS curve                  8
  Nakagawa, 2006     Japan         A116/S76/O18    210 (151/59)   62.6         I-II142/III68      T          intensity+-++   73 (34.8%)              NR (1--60 m)            NO (NSCLC+T)/Positive (S+T)             OS NR/OS R                8
  Woenckhaus, 2007   Germany       A74/S209/O69    487 (NR)       NR           NR                 T (C+N)    ≥10%            352 (72.3%)             27 m (0--200 m)         NO (NSCLC+C)/NO (NSCLC+N)               OS curve/OS curve         7
  Zheng, 2008        China+Japan   A86/S37/O32     155 (105/50)   69.5         I-II115/III-IV37   T (C+N)    \>5%            91 (58.7%)/21 (13.5%)   20.4 m (1--144 m)       NO (NSCLC+C)/Positive (A+C)             OS curve/OS curve         7
  Takanami, 2008     Japan         A105/S70/O6     181 (130/51)   65.5         I-II126/III55      T          ≥5%             74 (40.9%)              75.2 m (60--108 m)      NO (NSCLC+T)/Positive (S+T)             PFS, OS curve/PFS, OS R   8
  Bircan, 2010       Turkey        A18/S28         46 (42/4)      61.4         II3/III-IV37       C          \>5%            39 (84.8%)              261.8 d (10--800 d)     NO (NSCLC+C)                            OS R                      7
  Berardi, 2012      Italy         A192/S172/O75   439 (374/65)   68           I-II333/III106     T (C+N)    \>5%            284 (67%)/79 (18.6%)    42.5 m (10.6--87.2 m)   Negative (NSCLC+C)/Positive (NSCLC+N)   OS NR/OS R                7
  Wang, 2014         China         A71/S23/O4      98 (60/38)     63           NR                 T          intensity++     26 (26.5%)              42.8 m (6.87--69 m)     NO (NSCLC+T)                            DFS curve                 8
  Takagi, 2015       Japan         A110            110 (55/55)    67.9         I-II101/III9       C          \>10%           27 (24.5%)              71 m (6--88 m)          Negative (A+C)                          DFS, OS R                 7
  Yaman, 2015        Turkey        A45/S23/O12     80 (71/9)      59           I-II50/III-IV30    T          \>5%            26 (32.1%)              41.4 m (1--91 m)        NO (NSCLC+T)/Negative (A+T)             OS NR/OS Curve            8
  Matsuoka, 2016     Japan         S101            101 (92/9)     NR           I-II90/III11       T (C+N)    \>10%           25 (24.6%)              50 m (2--119 m)         Negative (S+C)                          DFS, DSS R                9
  Ohno, 2018         Japan         A181            181 (87/94)    69.7         I181               T (C+N)    \>10%           45 (24.9%)              74 m (12--151 m)        Negative (A+C)                          DFS, DSS R                9

Abbreviations: A, adenocarcinoma; C, cytoplasm; F, female; m, month; M, male; No., number; N, nucleus; NR, not reported; O, other type non-small lung cancer; R, reported in text; S, squamous cell carcinoma; T, total, T = C+N.

Association between MASPIN and NSCLC prognosis {#sec3-2}
----------------------------------------------

The differences in MASPIN expression and subcellular localization were analyzed in six studies. As a result, we found that up-regulated MASPIN nucleus and cytoplasm expression was associated with poor OS in NSCLC (HR = 1.43, 95% CI = 1.01--2.04, *P*\<0.05) without obvious heterogeneity (*I*^2^ = 33.00%, *P*~h~\<0.05, [Figure 2](#F2){ref-type="fig"}A). The results also showed that elevated MASPIN cytoplasm expression was associated with poor DFS in NSCLC (HR = 1.95, 95% CI = 1.31--2.88, *P*=0.001) without obvious heterogeneity (*I*^2^ = 42.90%, *P*~h~=0.001, [Figure 2](#F2){ref-type="fig"}A). Additionally, similar results were observed with DSS in NSCLC (HR = 2.17, 95% CI = 1.18--3.99, *P*=0.013) without obvious heterogeneity (*I*^2^ = 0.00%, *P*~h~=0.013, [Figure 2](#F2){ref-type="fig"}A). In order to uncover the effect of MASPIN cytoplasm localization on OS, we conducted a subgroup analysis, and the results showed that MASPIN overexpression was associated with poor OS in NSCLC (HR = 1.45, 95% CI = 1.01--2.07, *P*\<0.05, [Figure 2](#F2){ref-type="fig"}B) and LUAD (HR = 1.44, 95% CI = 0.33--6.26, *P*=0.626, [Figure 2](#F2){ref-type="fig"}C). In summary, our results showed a statistically negative interaction between MASPIN and NSCLC prognosis, and MASPIN might be a promising prognostic signature in NSCLC.

![Forest plot of the HR for the correlation between survival rate and MASPIN expression\
(**A**) The association of MASPIN expression with OS, PFS, DFS, and DSS. (**B,C**) The association of MASPIN expression with OS by subgroup analysis. (**D**) Sensitivity analysis of OS. (**E**) Publication bias analysis of OS by funnel plot. (**F**) Publication bias analysis of OS by Egger's test. Abbreviations: C, cytoplasm; CI, confidence interval; N, nucleus; T, total, T = C+N.](bsr-40-bsr20200743-g2){#F2}

Association between MASPIN and clinicopathological characteristics of NSCLC {#sec3-3}
---------------------------------------------------------------------------

Not all the included studies discussed the interaction between MASPIN and clinicopathological characteristics of NSCLC. Nine studies showed a higher MASPIN nucleus and cytoplasm expression was detected in male NSCLC patients than female NSCLC patients (OR = 1.71, 95% CI = 1.31--2.23, *P*\<0.001, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}A). The old NSCLC patients had an elevated MASPIN nucleus and cytoplasm expression than young patients (OR = 1.41, 95% CI = 1.04--1.91, *P*=0.027, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}B). LUSC patients had a lower MASPIN nucleus and cytoplasm expression than LUAD patients (OR = 0.25, 95% CI = 0.13--0.47, *P*\<0.001, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}C). The patients with stage T1 exposed MASPIN nucleus and cytoplasm underexpression compared with those with stages T2--T4 (OR = 1.82, 95% CI = 1.08--3.07, *P*=0.024, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}D). MASPIN nucleus and cytoplasm expression was not related to clinical stage, differentiation, and lymph node metastasis of NSCLC (OR = 1.81, 95% CI = 0.94--3.50, *P*=0.078; OR = 0.93, 95% CI = 0.62--1.41, *P*=0.74 and OR = 1.15, 95% CI = 0.68--1.96, *P*=0.604, respectively, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}E--G). Moreover, NSCLC patients with pleural invasion displayed MASPIN nucleus and cytoplasm overexpression than those without with pleural invasion (OR = 1.71, 95% CI = 1.08--2.72, *P*=0.023, Supplementary Table S2, [Figure 3](#F3){ref-type="fig"}H). As for MASPIN cytoplasm expression, the subgroup analysis results were generally consistent with the MASPIN nucleus and cytoplasm expression (Supplementary Table S2, [Figure 4](#F4){ref-type="fig"}).

![Forest plot for the relationship between total (cytoplasmic + nuclear) MASPIN expression and clinicopathological parameters of NSCLC\
(**A**) Gender (male versus female); (**B**) age (old versus young); (**C**) type (LUAD versus LUSC); (**D**) T stage (T2--4 versus T1); (**E**) TNM stage (III-IV vs I-II); (**F**) lymph node metastasis (LN+ vs LN−); (**G**) differentiation (poor versus well); (**H**) pleural invasion (yes versus no).](bsr-40-bsr20200743-g3){#F3}

![Forest plot for the relationship between cytoplasmic MASPIN expression and clinicopathological parameters of NSCLC\
(**A**) Gender (male versus female); (**B**) age (old versus young); (**C**) type (LUAD versus LUSC); (**D**) T stage (T2--4 versus T1); (**E**) TNM staging (III-IV vs I-II); (**F**) lymph node metastasis (LN+ vs LN−); (**G**) differentiation (poor versus well); (**H**) pleural invasion (yes versus no).](bsr-40-bsr20200743-g4){#F4}

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

A sensitivity analysis of OS was performed to verify the robustness of consequences. The results disclosed there had no significant heterogeneity ([Figure 2](#F2){ref-type="fig"}D). The sensitivity analysis and assessment of publication bias with PFS, DFS, and DSS were not conducted because there were few numbers of included studies. The funnel plot indicated no publication bias analysis of OS ([Figure 2](#F2){ref-type="fig"}E). Moreover, Egger's test revealed no obvious publication bias (*P*=0.795, [Figure 2](#F2){ref-type="fig"}F).

The prognostic significances of *SERPINB5* in NSCLC {#sec3-5}
---------------------------------------------------

The bioinformatics analysis results, perform by UALCAN, showed that *SERPINB5* mRNA expression was higher in both LUAD and LUSC patients than the normal (*P*\<0.001, [Figure 5](#F5){ref-type="fig"}). The Human Pathology Atlas illustrated that *SERPINB5* protein expression was significantly higher in both LUAD and LUSC than normal lung ([Figure 6](#F6){ref-type="fig"}). Next, OS was analyzed in NSCLC, LUAD, and LUSC related to *SERPINB5* mRNA expression, and we found that NSCLC and LUAD patients with high expression of *SERPINB5* mRNA had poorer prognosis (HR = 1.69, 95% CI = 1.47--1.95, *P*\<0.001; HR = 1.88, 95% CI = 1.49--2.38, *P*\<0.001; respectively, [Figure 7](#F7){ref-type="fig"}A,B), and there was no statistically difference in LUSC patients (HR = 0.79, 95% CI = 0.61--1.03, *P*=0.081, [Figure 7](#F7){ref-type="fig"}C). Additionally, the same trend was observed during the PFS analysis ([Figure 7](#F7){ref-type="fig"}D--F).

![Transcriptional expression of *SERPINB5* in LUAD and LUSC (UALCAN)\
(**A**) LUAD; (**B**) LUSC. \*\*\**P*\<0.001.](bsr-40-bsr20200743-g5){#F5}

![Representative proteins expressions of IHC images of distinct MASPIN were detected in LUAD, LUSC, and normal tissues (Human Protein Atlas)\
(**A**) MASPIN proteins were found not or low expressed in normal lung tissues. (**B,C**) Significantly high staining expressions were observed in LUAD and LUSC.](bsr-40-bsr20200743-g6){#F6}

![*SERPINB5* expression is correlated with the survival rate of non-small lung cancer patients using the Kaplan--Meier plotter website\
(**A--C**) The OS rate was related to SERPINB5 mRNA expression in NSCLC, LUAD, and LUSC. (**D--F**) PFS was related to SERPINB5 mRNA expression in NSCLC, LUAD, and LUSC.](bsr-40-bsr20200743-g7){#F7}

The clinicopathological significances of *SERPINB5* in NSCLC {#sec3-6}
------------------------------------------------------------

According to Kaplan--Meier plotter, higher *SERPINB5* mRNA expression was negatively correlated with OS of LUSC, T3 and T4 and stage III (*P*\<0.05, [Table 2](#T2){ref-type="table"}), and positively correlated with gender (male and female), smoking and non-smoking, LUAD, T1 and T2, N and stages I and II, (non-) chemotherapy, (non-) radiotherapy and surgical margins negative (*P*\<0.05, [Table 2](#T2){ref-type="table"}). There appeared a positive correlation between *SERPINB5* mRNA overexpression and PFS in gender (male and female), smoking and non-smoking, histology (LUAD and LUSC), T1, N0 and N2, stage I, (non-) chemotherapy, (non-) radiotherapy and surgical margins negative (*P*\<0.05, [Table 2](#T2){ref-type="table"}), whereas negative relationship in T2 and T3, N1 and stage II (*P*\<0.05, [Table 2](#T2){ref-type="table"}).

###### The prognostic significance of SERPINB5 mRNA in non-small lung cancer by Kaplan--Meier plotter

  Clinicopathological features   OS                   PFS                            
  ------------------------------ -------------------- ---------- ------------------- ----------
  **Sex**                                                                            
  Male                           1.69 (1.41--2.03)    9.40E-09   1.59 (1.21--2.09)   8.20E-04
  Female                         1.55 (1.23--1.96)    1.90E-04   1.32 (0.94--1.87)   1.10E-01
  **Smoking**                                                                        
  Yes                            1.7 (1.38--2.09)     3.90E-07   1.49 (1.12--1.97)   5.60E-03
  No                             2.23 (1.27--3.89)    3.90E-03   1.83 (1.13--2.96)   1.30E-02
  **Histology**                                                                      
  Adenocarcinoma                 1.88 (1.49--2.38)    7.10E-08   1.96 (1.44--2.68)   1.60E-05
  Squamous                       0.79 (0.617--1.03)   8.10E-02   1.68 (0.97--2.9)    6.10E-02
  **T**                                                                              
  1                              1.71 (1.28--2.3)     2.80E-04   1.49 (0.81--2.75)   2.00E-01
  2                              1.53 (1.17--1.99)    1.70E-03   0.82 (0.6--1.11)    1.90E-01
  3                              0.66 (0.37--1.19)    1.67E-01   0.62 (0.22--1.76)   3.60E-01
  4                              0.64 (0.34--1.23)    1.80E-01                       
  **N**                                                                              
  0                              1.53 (1.24--1.89)    7.50E-05   1.31 (0.91--1.87)   1.40E-01
  1                              1.37 (1--1.87)       5.00E-02   0.74 (0.47--1.17)   1.90E-01
  2                              1.48 (0.91--2.41)    1.10E-01   2.73 (1.22--6.09)   1.10E-02
  **TNM stage**                                                                      
  I                              2.08 (1.59--2.72)    4.80E-08   2.05 (1.31--3.2)    1.30E-03
  II                             1.23 (0.86--1.78)    2.60E-01   0.4 (0.22--0.73)    1.70E-03
  III                            0.76 (0.43--1.34)    3.40E-01                       
  **Chemotherapy**                                                                   
  Yes                            2.41 (1.58--3.68)    2.60E-05   1.66 (1.08--2.57)   2.00E-02
  No                             2.26 (1.62--3.17)    1.00E-06   1.57 (1.03--2.37)   3.30E-02
  **Radiotherapy**                                                                   
  Yes                            3.94 (2.2--7.05)     9.30E-07   2.16 (1.24--3.78)   5.70E-03
  No                             1.76 (1.22--2.53)    2.00E-03   1.37 (0.89--2.12)   1.50E-01
  **Surgery success**                                                                
  Surgical margins negative      2.25 (1.79--2.84)    1.40E-12   1.85 (1.39--2.46)   2.20E-05

DNA methylation of *SERPINB5* and its correlation with mRNA expression in NSCLC patients {#sec3-7}
----------------------------------------------------------------------------------------

To recognize the role of methylation in regulating *SERPINB5* expression in NSCLC patients, MethHC was applied to explore the level of DNA methylation in the *SERPINB5* gene promoter region and its correlation with mRNA expression. The difference of the *SERPINB5* methylation level between LUAD and normal samples was statistically significant (*P*\<0.005, [Figure 8](#F8){ref-type="fig"}A). Additionally, *SERPINB5* methylation was negatively correlated with its mRNA expression in LUAD (r = −0.128, *P*\<0.001, [Figure 8](#F8){ref-type="fig"}B). The statistically significant results were also indicated in LUSC patients ([Figure 8](#F8){ref-type="fig"}C,D).

![DNA methylation of the *SERPINB5* gene promoter region in non-small lung cancer (MethHC)\
(**A**) Comparison of DNA methylation levels of the *SERPINB5* gene in LUAD with normal tissues. (**B**) The correlation between DNA methylation and mRNA expression in the *SERPINB5* gene of LUAD. (**C**) Comparison of DNA methylation levels of the *SERPINB5* gene in LUSC with normal tissues. (**D**) The correlation between DNA methylation and mRNA expression in the *SERPINB5* gene of LUSC. Green indicates normal lung tissues, red represents non-small lung cancer tissues.](bsr-40-bsr20200743-g8){#F8}

Function and pathway enrichment analysis of *SERPINB5*-related genes in LUAD {#sec3-8}
----------------------------------------------------------------------------

To comprehend the functions and potential mechanisms of *SERPINB5* in NSCLC, cBioPortal \[[@B25]\] was used to identify *SERPINB5*-related genes in LUAD. There were 85 genes with Spearman's correlation coefficients more than 0.4 and were identified as *SERPINB*-related genes in TCGA-LUAD. Besides, 85 genes were put into the DAVID \[[@B26],[@B27]\] for GO and KEGG pathway enrichment analysis, revealing 20 GO terms (Supplementary Table S3) and 3 KEGG pathways (Supplementary Table S4) with statistical significance. These corresponding GO terms were considered as the most specific and useful for describing the concrete function of *SERPINB5* in LUAD, the interaction between different GO terms were visualized as three GO maps ([Figure 9](#F9){ref-type="fig"}A--C). KEGG pathway enrichment analysis results subjected that the genes were enriched in amoebiasis, metabolic pathways, and small cell lung cancer ([Figure 9](#F9){ref-type="fig"}D).

![Dot plot of GO enrichment and KEGG pathways analyses from the predicted *SERPINB5*-related genes\
(**A**) Biological process; (**B**) Cellular component; (**C**) Molecular function; (**D**) KEGG.](bsr-40-bsr20200743-g9){#F9}

Discussion {#sec4}
==========

Up to date, more and more studies are emerging to investigate MASPIN expression and its roles in malignant tumors, and carry out in-depth researches on different mechanisms of MASPIN about inhibiting tumor cell plasticity and affecting the context-dependent response to drugs \[[@B15]\]. Nevertheless, only a minority of MASPIN expression and subcellular localization were evaluated in NSCLC and no unanimous agreement was reached. One study announced that MASPIN cytoplasm expression alone could be a useful negative prognostic effect in p-stage IA LUAD \[[@B33]\]. Other studies indicated strong MASPIN nuclear expression was an independent favorable prognostic factor in NSCLC \[[@B29],[@B40]\], and it improved differentiated epithelial phenotypes, decreased tumor angiogenesis, and increased tumor sensitivity to drug-induced apoptosis \[[@B41]\]. In contrast, Bircan et al. indicated MASPIN had no prognostic significance although it was higher in both LUSC and LUAD \[[@B42]\]. There is no doubt that larger studies are urgently needed to reveal the exact role of MASPIN in the occurrence, development, and prognosis of NSCLC. Hence, we summarized 12 studies with 2220 patients, which met preordained inclusion criteria and had high quality according to NOS scores, to obtain more accurate results and further explored the mechanism of MASPIN in NSCLC through different online databases.

Clinical data conflict on the prognostic utility of MASPIN \[[@B29],[@B36],[@B43]\], and we found that MASPIN expression was up-regulated in NSCLC and was closely related to prognosis. Importantly, we not only analyzed the relationship between MASPIN and NSCLC prognosis but also applied different subcellular localization. Our results suggested that MASPIN was statistically correlated with poor prognosis (OS, DFS, and DSS) regarding different subcellular localization (nucleus and cytoplasm or cytoplasm alone), which indicated MASPIN might be a promising prognostic signature in NSCLC, although the nuclear-cytoplasmic expression pattern might have stronger influences on metastasis and proliferation than nuclear expression alone \[[@B36]\]. Our subgroup analysis showed that rising MASPIN protein was associated with poor OS in LUAD patients with no statistical difference (*P*=0.626) while the results from the Kaplan--Meier plotter uncovered that negative correlation between *SERPINB5* mRNA and OS and PFS was statistically significant in LUAD patients (*P*\<0.001). In addition, the results of LUAD and LUSC were not identical. The discrepancies might be largely attributable to background heterogeneity, which suggests that larger sample size of clinically relevant studies may be needed to verify this phenomenon. But although LUSC and LUAD account for a large proportion of NSCLC \[[@B44]\], they still do not fully reflect all NSCLC.

In addition, we analyzed the relationship between MASPIN and clinicopathological characteristics from the perspective of meta-analysis and Kaplan--Meier plotter. The results were complementary, as one focused on subcellular localization and the other on prognosis; one is the protein condition and the other is the RNA condition. However, it is found that the expression of both *SERPINB5* protein and mRNA is significantly correlated with various clinicopathological characteristics and survival outcomes. Many studies have revealed the relevant mechanism between MASPIN and the occurrence, development, treatment, and prognosis of lung cancer. In LUAD cells, MASPIN can not only down-regulate the expression of matrix metalloproteinase-2 and integrin β1 to significantly inhibit cell migration and invasion but also affect cell growth mainly by targeting AKT signaling molecules. The different functions of MASPIN may be due to its different molecular characteristics \[[@B45]\]. One study suggested that cytoplasmic MASPIN may play an important role in LUAD by regulating apoptosis and, thus, is a favorable prognostic marker for LUAD patients, whereas the nuclear location may be linked to the promotion of angiogenesis \[[@B46]\]. Others hold MASPIN inhibits cell motility by suppressing Rac1 and PAK1 activity \[[@B47]\], promotes cell adhesion via the PI3K/ERK pathway \[[@B47],[@B48]\], and suppresses survival of lung cancer cells through modulation of AKT pathway \[[@B49],[@B50]\]. It was suggested that the loss-expression of MASPIN may participate in the invasion and metastasis of NSCLC and it has a positive relationship to vasculogenic mimicry in NSCLC \[[@B51]\]. About the treatment, resistance to osimertinib partially arises through MASPIN \[[@B52]\] and a novel statistical methodology for detecting splicing changes in exon array data presented that *SERPINB5* showed alternative splicing in NSCLC patients treated with bevacizumab/erlotinib \[[@B53]\].

To uncover additional mechanisms, we performed methylation analysis. Online databases from MethHC showed that the underlying mechanism of MASPIN affecting NSCLC survival outcomes may be related to hypomethylation and this was following a previous study \[[@B54]\], and this difference may be critical for epigenetic regulation of radiosensitivity \[[@B55]\]. And then, in this study, we demonstrated that *SERPINB5* in both LUAD and LUSC were lowly methylated in the promoter region and that there was an inverse correlation between DNA methylation and mRNA expression. Hypomethylated status means activation of gene expression, therefore, it is not difficult to infer that *SERPINB5* methylation partially contributes to its increased expression and plays an important role in the occurrence and development in NSCLC. Given the statistical difference between *SERPINB5* mRNA and prognosis in LUAD and not in LUAC, TCGA-LUAD was selected for the subsequent analysis of co-expressed genes and enrichment to confirmed that *SERPINB5* influenced related pathways involving the neighboring genes, as is mentioned in a previous study \[[@B53],[@B56]\], and future investigations and validation are needed.

Sensitivity analysis demonstrated that the correlation between MASPIN and NSCLC prognosis was stable and unchanged after removing any one study. Funnel plot and Egger's test were used to detect publication bias and events indicated no obvious publication bias.

However, the present study was not without limitations. Foremost, all the data analyzed in our study were obtained from other published studies or different online databases, which might cause background heterogeneity, as mentioned earlier. Additionally, eight studies were conducted in Asia (China or Japan) which may result in an excursion in race. Later multinational and multiracial studies for this specific population are needed. Third, the included studies had different definitions of MASPIN cut-off value. Therefore, before carrying out relevant researches, it may be necessary to identify the cut-off value in a unified way. Fourth, according to Kaplan--Meier plotter, higher *SERPINB5* mRNA expression was positively correlated with OS and PFS of surgery success (surgical margins negative) (all *P*\<0.0001). Due to the limitations of the data obtained, we could only divide the surgery success into one group, which was bound to cause the loss of information, and the later data with richer dimensions is warranted. Finally, a series of silico-bioinformatic analysis was performed to uncover the promising molecular mechanisms of MASPIN in NSCLC, and more elaborate studies are required to be designed and conducted to validate these results in the future.

In conclusion, our study demonstrated that MASPIN had a statistically negative correlation with NSCLC prognosis, functioning as an oncoprotein by hypomethylation and influencing specific pathways, which lays a foundation for MASPIN to develop into an independent prognostic factor for NSCLC patients.
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